Minocycline Treatment for Cystoid Macular Edema

Last updated: April 16, 2023
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

1/2

Condition

Cystoid Macular Edema

Macular Edema

Treatment

N/A

Clinical Study ID

NCT05474950
MINOCME
  • Ages 18-70
  • All Genders

Study Summary

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participant diagnosed with CME.
  • Participant aged from 18-60 years old.
  • Participant that signed the informed consent document and is able to complete thefollowing visits.

Exclusion

Exclusion Criteria:

  • Participant is allergy to minocycline or tetracyclines.
  • Participant has no contraindications of minocycline or tetracyclines.
  • Participant has an abnormal function of liver, heart, kidney and thyroid.
  • Female that is pregnant, breast-feeding or planning to become pregnant.
  • Participant that is currently using other medications.

Study Design

Total Participants: 5
Study Start date:
January 01, 2019
Estimated Completion Date:
June 01, 2025

Connect with a study center

  • Zhongshan Ophthalmic Center

    Guangzhou, Guangdong 510000
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.